[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354709-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354709-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-the-parp10-bcat2-axis-disrupts-branched-chain-amino-acid-metabolism-to-suppress-bone-metastasis-in-lung-cancer","Targeting the PARP10-BCAT2 axis disrupts branched-chain amino-acid metabolism to suppress bone metastasis in lung cancer","","Lung cancer bone metastasis is a major clinical problem driven by therapeutic resistance and severe morbidity. By analyzing bulk RNA sequencing of bone metastatic tumors across cancer types, the study identifies PARP10 as a consistently upregulated gene and links high PARP10 expression to poor patient survival. PARP10 promotes lung cancer growth and bone metastasis in vitro and in vivo, inducing DNA damage and oxidative stress while enhancing BCAT2 expression via MYC to increase BCAA catabolism. This shifts tumor metabolism to suppress osteoclast differentiation, reducing metastasis. Pharmacologic PARP10 inhibition with OUL232 mitigates metastatic burden in mice without observable toxicity, simultaneously triggering apoptosis and disrupting the pro-metastatic niche.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-the-parp10-bcat2-axis-disrupts-branched-chain-amino-acid-metabolism-to-suppress-bone-metastasis-in-lung-cancer/354709/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-the-parp10-bcat2-axis-disrupts-branched-chain-amino-acid-metabolism-to-suppress-bone-metastasis-in-lung-cancer/354709.png","ImageObject",300,407,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes bone metastasis in lung cancer difficult to treat?","Question",{"text":63,"@type":64},"Bone metastasis in lung cancer presents major challenges due to therapeutic resistance and severe morbidity, with poor survival once it occurs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PARP10 contribute to lung cancer bone metastasis?",{"text":68,"@type":64},"PARP10 supports tumor growth and bone metastasis by causing DNA damage and oxidative stress and by promoting MYC-dependent BCAT2 expression that enhances BCAA catabolism.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does inhibiting the PARP10-BCAT2 axis suppress bone metastasis?",{"text":72,"@type":64},"PARP10-driven BCAA catabolism creates an adaptive metabolic compensation in tumor cells while depleting BCAA in the bone microenvironment, suppressing osteoclast differentiation and reducing metastatic progression. OUL232 inhibition decreases metastatic burden in mice and induces tumor-cell apoptosis while disrupting the pro-metastatic niche.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354709,1790189281,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nTargeting the PARP10-BCAT2 axis disrupts branched-chain amino-acid metabolism to suppress bone metastasis in lung cancer  \nYahan Qin 1,2,5, Ke Xue1,2,5, Yujian Xu1,2, Hongyu Pan1,2, Wenjun Chai 1,2, Lei Sun1,2, Xiaoli Liu1,2, Jing Li1,2, Yue Cao1,2, Jing Li3, Qian Liu4 ✉ and Mingxia Yan1,2 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Lung cancer bone metastasis presents a major clinical challenge due to therapeutic resistance and severe morbidity. Although disrupting tumor-bone microenvironment crosstalk is a promising strategy, clinically actionable targets remain limited. Here, by analyzing bulk RNA sequencing data from bone metastatic tumors across multiple cancer types, we identiﬁed PARP10 as a gene consistently upregulated in bone metastases. High PARP10 expression in primary tumors was correlated with poor patient survival. Functional studies demonstrated that PARP10 promoted lung cancer growth and bone metastasis both in vitro and in vivo. Mechanistically, multi-omics integrated analyses revealed that PARP10 deletion induced DNA damage and oxidative stress, and upregulated BCAT2 expression in a MYC-dependent manner to enhance BCAA catabolism. This metabolism exerts an adaptive compensatory effect on tumor cells via boosting mitochondrial oxidative phosphorylation, yet depletes bone microenvironmental BCAA and consequently suppresses osteoclast differentiation, thereby inhibiting bone metastasis. Importantly, pharmacological inhibition of PARP10 with OUL232 mitigated bone metastatic burden in mice without observable toxicity, demonstrating its therapeutic potential by concurrently inducing tumor cell apoptosis and disrupting the pro-metastatic niche. Our ﬁndings establish PARP10 as a central regulator of a targetable metabolic competition axis and propose its inhibition as a dual-mechanism strategy |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| that simultaneously attacks tumor cells and disrupts the pro-metastatic niche. |  |  |\n|  | Cell Death and Disease (2026)17:763; [https://doi.org/10.1038/s41419-026-08989-3](https://doi.org/10.1038/s41419-026-08989-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nLung cancer ranks among the most prevalent malignancies globally and is the leading cause of cancer-related mortality worldwide, posing a signiﬁcant threat to human health [1] . Lung adenocarcinoma (LUAD) is the most common subtype, accounting for approximately half of all lung cancer cases. Bone metastasis is a frequent and severe complication in advanced stages of LUAD [2] . Once bone metastasis occurs, the 5-year survival rate drops to \u003C10%[3, 4] . Current treatments, including localized radiotherapy, surgery, systemic chemotherapy, targeted therapy, and immunotherapy, can improve patients’ quality of life to some extent, but the prognosis remains poor [5–8] . Therefore, elucidating the mechanisms of bone metastasis in LUAD and identifying novel therapeutic targets are urgent research priorities.  \nThe development of poly (ADP-ribose) polymerase (PARP) inhibitors marks a major advance in cancer therapy. PARPs are a family of multifunctional enzymes that mediate post-translational modiﬁcations, with core roles in DNA damage repair andapoptotic regulation [9] . Among the 17-member PARP family, PARP1, PARP2, and PARP3 are primarily involved in DNA damage repair [10], whereas others like PARP10, PARP5A, and PARP5B are  \nassociated with cellular metabolism and energy homeostasis [11–13] . PARP inhibitors are the ﬁrst class of clinically successful drugs based on “synthetic lethality” [14] . Leveraging this mechanism, these inhibitors are particularly effective against tumor cells with pre-existing homologous recombination repair (HRR) deﬁciencies caused by mutations in genes such as BRCA1/2, ATM, or PALB2 [15–18] . Conventional PARP inhibitors primarily target PARP1/2, and have ","cbCaisaPjgVsaPa3","https://ap.wps.com/l/cbCaisaPjgVsaPa3","pdf",17559563,21,"English","# Introduction\n## PARP inhibitors and limitations in lung cancer\n## PARP10 catalytic specificity and links to metabolism\n## Study rationale for LUAD bone metastasis\n## Overview of experimental approach and findings","[{\"question\":\"What makes bone metastasis in lung cancer difficult to treat?\",\"answer\":\"Bone metastasis in lung cancer presents major challenges due to therapeutic resistance and severe morbidity, with poor survival once it occurs.\"},{\"question\":\"How does PARP10 contribute to lung cancer bone metastasis?\",\"answer\":\"PARP10 supports tumor growth and bone metastasis by causing DNA damage and oxidative stress and by promoting MYC-dependent BCAT2 expression that enhances BCAA catabolism.\"},{\"question\":\"Why does inhibiting the PARP10-BCAT2 axis suppress bone metastasis?\",\"answer\":\"PARP10-driven BCAA catabolism creates an adaptive metabolic compensation in tumor cells while depleting BCAA in the bone microenvironment, suppressing osteoclast differentiation and reducing metastatic progression. OUL232 inhibition decreases metastatic burden in mice and induces tumor-cell apoptosis while disrupting the pro-metastatic niche.\"}]","Targeting the PARP10-BCAT2 axis disrupts branched-chain amino-acid metabolism to suppress bone metastasis in lung cancer | PDF",1790113186,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cbbeae35080e9c168c27d9b2686b692.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fafebc542bd8bc1396c72945def29b1a.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1db4c179d2d1ba952f144372991e9808.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc61ac3363cc5ef798eaa771b7beb684.webp",980,1301]